Tetragon Partners GP
GRAND CAYMAN, E9files as Tetragon Partners GP Ltd
$614m in 32 US stocks at the end of 30 June 2026. The top 10 are 76.5% of the money. It changed about 12.2% of the portfolio this quarter.
Value
$614m
Stocks
32
Top 10 share
76.5%
Turnover
12.2%
What changed this quarter
New
Bought for the first time this quarter.
- Alkami TechnologyALKT1.8% of the fund
- CelcuityCELC1.1% of the fund
- Cue BiopharmaCUE0.5% of the fund
- Aclaris TherapeuticsACRS0.3% of the fund
- Monte Rosa TherapeuticsGLUE0.2% of the fund
Added
Bought more of a stock they already held.
- UiPathPATH54.8% of the fund+23%
- Definium TherapeuticsDFTX2.2% of the fund+44%
- MBX BiosciencesMBX1.8% of the fund+40%
- Relay TherapeuticsRLAY1.7% of the fund+214%
- Arrowhead PharmaceuticalsARWR1.7% of the fund+3%
- PharvarisPHVS1.7% of the fund+33%
- Alkermes plc.ALKS1.6% of the fund+19%
- ImmunovantIMVT1.6% of the fund+17%
- Silence TherapeuticsSLN1.4% of the fund+21%
- Dyne TherapeuticsDYN1.3% of the fund+38%
- Ionis PharmaceuticalsIONS1.3% of the fund+133%
- Agios PharmaceuticalsAGIO1.2% of the fund+25%
- Harmony Biosciences HoldingsHRMY1.2% of the fund+68%
- Acadia PharmaceuticalsACAD0.7% of the fund+16%
- Tectonic TherapeuticTECX0.3% of the fund+24%
Cut
Sold some of their stake.
- Celldex TherapeuticsCLDX1.8% of the fund-7%
- AnnexonANNX1.2% of the fund-4%
- Warner Bros. DiscoveryWBD1.1% of the fund-73%
- Nektar TherapeuticsNKTR1.0% of the fund-16%
- Amylyx PharmaceuticalsAMLX0.9% of the fund-6%
Sold out
Sold their entire stake.
- Praxis Precision MedicinesPRAX-100%
- Soleno Therapeutics-100%
- Axsome TherapeuticsAXSM-100%
- MapLight TherapeuticsMPLT-100%
- Aardvark TherapeuticsAARD-100%
- Ultragenyx PharmaceuticalRARE-100%
- Karyopharm TherapeuticsKPTI-100%
Holdings
- Kolibri Global EnergyKGEI
- Share
- 5.5%
- Value
- $34m
- Shares
- 6,834,504
Held
- Autolus TherapeuticsAUTL
- Share
- 2.5%
- Value
- $15m
- Shares
- 9,500,000
Held
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| UiPathPATH | 54.8% | $336m | 30,950,000 | +23% |
| Kolibri Global EnergyKGEI | 5.5% | $34m | 6,834,504 | Held |
| Autolus TherapeuticsAUTL | 2.5% | $15m | 9,500,000 | Held |
| LyftLYFT | 2.4% | $15m | 1,000,000 | Held |
| Definium TherapeuticsDFTX | 2.2% | $14m | 286,990 | +44% |
| WorkivaWK | 2.0% | $12m | 250,000 | Held |
| SprinklrCXM | 1.8% | $11m | 2,200,000 | Held |
| MBX BiosciencesMBX | 1.8% | $11m | 203,543 | +40% |
| Alkami TechnologyALKT | 1.8% | $11m | 600,284 | New |
| Celldex TherapeuticsCLDX | 1.8% | $11m | 290,441 | -7% |
| Relay TherapeuticsRLAY | 1.7% | $11m | 570,311 | +214% |
| Arrowhead PharmaceuticalsARWR | 1.7% | $11m | 130,484 | +3% |
| PharvarisPHVS | 1.7% | $10m | 295,627 | +33% |
| Alkermes plc.ALKS | 1.6% | $10m | 189,979 | +19% |
| ImmunovantIMVT | 1.6% | $10m | 255,934 | +17% |
| Silence TherapeuticsSLN | 1.4% | $8m | 764,256 | +21% |
| Dyne TherapeuticsDYN | 1.3% | $8m | 356,657 | +38% |
| Ionis PharmaceuticalsIONS | 1.3% | $8m | 97,173 | +133% |
| Agios PharmaceuticalsAGIO | 1.2% | $8m | 205,579 | +25% |
| Harmony Biosciences HoldingsHRMY | 1.2% | $7m | 201,036 | +68% |
| Krystal BiotechKRYS | 1.2% | $7m | 19,668 | Held |
| AnnexonANNX | 1.2% | $7m | 1,242,455 | -4% |
| CelcuityCELC | 1.1% | $7m | 64,110 | New |
| Warner Bros. DiscoveryWBD | 1.1% | $7m | 250,000 | -73% |
| Nektar TherapeuticsNKTR | 1.0% | $6m | 86,996 | -16% |
| Amylyx PharmaceuticalsAMLX | 0.9% | $5m | 297,926 | -6% |
| Acadia PharmaceuticalsACAD | 0.7% | $4m | 167,875 | +16% |
| Cue BiopharmaCUE | 0.5% | $3m | 93,819 | New |
| SnowflakeSNOW | 0.4% | $3m | 10,000 | Held |
| Aclaris TherapeuticsACRS | 0.3% | $2m | 400,000 | New |
| Tectonic TherapeuticTECX | 0.3% | $2m | 46,516 | +24% |
| Monte Rosa TherapeuticsGLUE | 0.2% | $1m | 56,052 | New |
Options (7)
- Axsome TherapeuticsAXSM
- Type
- Call
- Value
- $9m
- Contracts
- 35,000
- Ultragenyx PharmaceuticalRARE
- Type
- Call
- Value
- $3m
- Contracts
- 100,000
- Silence TherapeuticsSLN
- Type
- Call
- Value
- $3m
- Contracts
- 300,000
- Karyopharm TherapeuticsKPTI
- Type
- Call
- Value
- $2m
- Contracts
- 250,300
- Agios PharmaceuticalsAGIO
- Type
- Call
- Value
- $2m
- Contracts
- 50,000
- Tenax TherapeuticsTENX
- Type
- Call
- Value
- $1m
- Contracts
- 75,100
- Amylyx PharmaceuticalsAMLX
- Type
- Call
- Value
- $152,660
- Contracts
- 8,500
| Company | Type | Value | Contracts |
|---|---|---|---|
| Axsome TherapeuticsAXSM | Call | $9m | 35,000 |
| Ultragenyx PharmaceuticalRARE | Call | $3m | 100,000 |
| Silence TherapeuticsSLN | Call | $3m | 300,000 |
| Karyopharm TherapeuticsKPTI | Call | $2m | 250,300 |
| Agios PharmaceuticalsAGIO | Call | $2m | 50,000 |
| Tenax TherapeuticsTENX | Call | $1m | 75,100 |
| Amylyx PharmaceuticalsAMLX | Call | $152,660 | 8,500 |
Over time and by industry
Value over time
Jun '25
Dec '25
Jun '26
Value is up 73.5% since 30 June 2025.
Where the money is
Technology63.1%
Health care27.8%
Energy5.5%
Media & telecom1.1%
Other2.5%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.